Delayed
Nasdaq
04:30:00 2024-05-08 pm EDT
|
5-day change
|
1st Jan Change
|
4.1
USD
|
+0.24%
|
|
0.00%
|
-40.36%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
339.5
|
29.73
|
63.43
|
37.82
|
-
|
-
|
Enterprise Value (EV)
1 |
339.5
|
29.73
|
63.43
|
37.82
|
37.82
|
37.82
|
P/E ratio
|
-12.4
x
|
-1.37
x
|
-0.9
x
|
-0.95
x
|
-0.66
x
|
-0.61
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.58
x
|
1.24
x
|
28.3
x
|
-
|
-
|
-
|
EV / Revenue
|
5.58
x
|
1.24
x
|
28.3
x
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-47,256,040
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
4,347
|
5,039
|
9,226
|
9,225
|
-
|
-
|
Reference price
2 |
78.10
|
5.899
|
6.875
|
4.100
|
4.100
|
4.100
|
Announcement Date
|
3/29/22
|
4/14/23
|
3/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
55.24
|
60.88
|
23.9
|
2.239
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-13.39
|
-28.92
|
-38.08
|
-47.07
|
-57.65
|
-62.7
|
Operating Margin
|
-
|
-22%
|
-120.97%
|
-1,700.56%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-17.14
|
-18.72
|
-42.19
|
-45.22
|
-57.3
|
-62.5
|
Net income
1 |
20.12
|
-17.14
|
-18.74
|
-42.19
|
-45.22
|
-57.3
|
-62.5
|
Net margin
|
36.42%
|
-28.16%
|
-78.4%
|
-1,884.5%
|
-
|
-
|
-
|
EPS
2 |
-
|
-6.300
|
-4.300
|
-7.640
|
-4.305
|
-6.210
|
-6.770
|
Free Cash Flow
|
-
|
-7.185
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-11.8%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/17/21
|
3/29/22
|
4/14/23
|
3/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
14.68
|
11.06
|
11.8
|
6.351
|
3.59
|
2.161
|
0.5811
|
0.0855
|
1.267
|
0.305
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.987
|
-7.344
|
-6.707
|
-6.543
|
-7.807
|
-7.86
|
-7.402
|
-6.477
|
-5.323
|
-18.87
|
-9.681
|
-11.09
|
-12.24
|
-14.06
|
Operating Margin
|
-27.16%
|
-66.41%
|
-56.83%
|
-103.03%
|
-217.49%
|
-363.74%
|
-1,273.79%
|
-7,573.22%
|
-420%
|
-6,187.92%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-4.061
|
-11.55
|
1.078
|
-4.868
|
-7.076
|
-7.849
|
-7.354
|
-6.881
|
-5.102
|
-22.86
|
-9.065
|
-10.56
|
-11.83
|
-13.77
|
Net income
1 |
-4.061
|
-11.55
|
0.9859
|
-4.776
|
-7.076
|
-7.875
|
-7.354
|
-6.881
|
-5.102
|
-22.86
|
-9.065
|
-10.56
|
-11.83
|
-13.77
|
Net margin
|
-27.66%
|
-104.46%
|
8.35%
|
-75.21%
|
-197.12%
|
-364.42%
|
-1,265.5%
|
-8,045.94%
|
-402.59%
|
-7,493.77%
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.200
|
-4.700
|
0.2000
|
-1.100
|
-1.600
|
-1.800
|
-1.500
|
-1.400
|
-1.000
|
-7.260
|
-0.9600
|
-1.030
|
-1.105
|
-1.210
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/22/21
|
3/29/22
|
5/12/22
|
8/10/22
|
11/14/22
|
4/14/23
|
5/15/23
|
8/21/23
|
11/13/23
|
3/29/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-7.19
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
10.9
|
2.17
|
0.2
|
0.23
|
0.24
|
0.25
|
Capex / Sales
|
-
|
17.98%
|
9.06%
|
8.81%
|
-
|
-
|
-
|
Announcement Date
|
8/17/21
|
3/29/22
|
4/14/23
|
3/29/24
|
-
|
-
|
-
|
Average target price
15.5
USD Spread / Average Target +278.05% Consensus |
1st Jan change
|
Capi.
|
---|
| -40.36% | 37.82M | | +2.91% | 108B | | +10.26% | 105B | | +1.57% | 23.46B | | -12.22% | 21.72B | | -7.05% | 18.64B | | -37.64% | 17.45B | | -6.74% | 17.19B | | +6.38% | 13.99B | | +36.81% | 12.53B |
Bio Therapeutic Drugs
|